Founded in 2012, Genotox Laboratories offers actionable toxicology and pharmacogenetic services that provide enhanced medication monitoring and personalized medicine offerings to care providers.
Specifically, the firm provides DNA-based urine drug test (UDT) for verifying sample authenticity, as well as pharmacogenetic testing for predicting a patient’s expected response to certain drugs, based on their specific genetic makeup.
In 2017, the company made headlines by launching its ToxProtect solution, which matches a patient’s DNA to the DNA in a urine sample, and also identifies all types of substitute urine, including synthetic-urine products. This product is ideal in countering fake our counterfeit urine, which is often used by patients trying to hide their opioid use.
“Many people may not realize it, but there’s a quiet war going on out there aimed at defeating this important test,” says Dr. Matt McCarty, CEO of Genotox Laboratories, in this Physicians Daily article. “Using urine-drug testing that eliminates the risks of sample substitution by those motivated to do so will be a strong step in the right direction.”
These specialized services provide tremendous insights and value for pain physicians, family practices, internal medicine, psychiatrists, addiction specialists, OB/GYN, and recovery centers.
In addition, the company offers a dynamic physician portal that allows care providers to securely view, download, and print results anytime. These results can also be delivered via fax or through an EMR interface.
Genotox Laboratories is a prime example of an innovative company that is providing actionable lab insights to help arm caregivers with all of the patient insights they need to enhance overall care.